Camurus AB (publ) Logo

Camurus AB (publ)

0RD1.L

(0.0)
Stock Price

665,50 SEK

24.96% ROA

31.81% ROE

73.11x PER

Market Cap.

32.456.370.600,00 SEK

0% DER

0% Yield

25.13% NPM

Camurus AB (publ) Stock Analysis

Camurus AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Camurus AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Camurus AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Camurus AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Buy
4 Stoch RSI Sell

Camurus AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Camurus AB (publ) Revenue
Year Revenue Growth
2012 95.204.000
2013 197.716.000 51.85%
2014 208.207.000 5.04%
2015 154.799.000 -34.5%
2016 113.737.000 -36.1%
2017 54.308.000 -109.43%
2018 49.321.000 -10.11%
2019 105.605.000 53.3%
2020 335.997.000 68.57%
2021 600.570.000 44.05%
2022 956.340.000 37.2%
2023 1.535.940.000 37.74%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Camurus AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2012 54.818.000
2013 52.675.000 -4.07%
2014 114.146.000 53.85%
2015 150.997.000 24.41%
2016 172.077.000 12.25%
2017 222.939.000 22.81%
2018 207.664.000 -7.36%
2019 249.226.000 16.68%
2020 238.678.000 -4.42%
2021 388.688.000 38.59%
2022 473.757.000 17.96%
2023 590.768.000 19.81%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Camurus AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 14.505.000
2013 17.775.000 18.4%
2014 22.165.000 19.81%
2015 11.934.000 -85.73%
2016 17.985.000 33.64%
2017 26.590.000 32.36%
2018 21.999.000 -20.87%
2019 23.468.000 6.26%
2020 97.581.000 75.95%
2021 27.563.000 -254.03%
2022 35.248.000 21.8%
2023 41.664.000 15.4%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Camurus AB (publ) EBITDA
Year EBITDA Growth
2012 20.912.000
2013 122.785.000 82.97%
2014 61.323.000 -100.23%
2015 -28.337.000 316.41%
2016 -101.698.000 72.14%
2017 -240.377.000 57.69%
2018 -285.411.000 15.78%
2019 -357.382.000 20.14%
2020 -203.752.000 -75.4%
2021 -109.439.000 -86.18%
2022 73.668.000 248.56%
2023 430.100.000 82.87%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Camurus AB (publ) Gross Profit
Year Gross Profit Growth
2012 91.883.000
2013 196.141.000 53.15%
2014 207.551.000 5.5%
2015 154.562.000 -34.28%
2016 111.597.000 -38.5%
2017 52.952.000 -110.75%
2018 42.499.000 -24.6%
2019 82.318.000 48.37%
2020 300.713.000 72.63%
2021 515.218.000 41.63%
2022 853.075.000 39.6%
2023 1.407.960.000 39.41%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Camurus AB (publ) Net Profit
Year Net Profit Growth
2012 13.317.000
2013 99.235.000 86.58%
2014 48.346.000 -105.26%
2015 -159.542.000 130.3%
2016 -80.993.000 -96.98%
2017 -190.574.000 57.5%
2018 -234.676.000 18.79%
2019 -289.865.000 19.04%
2020 -167.265.000 -73.3%
2021 -90.446.000 -84.93%
2022 55.553.000 262.81%
2023 345.584.000 83.92%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Camurus AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 1
2013 4 100%
2014 2 -200%
2015 -6 116.67%
2016 -2 -200%
2017 -5 60%
2018 -6 16.67%
2019 -6 0%
2020 -3 -100%
2021 -2 -200%
2022 1 0%
2023 6 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Camurus AB (publ) Free Cashflow
Year Free Cashflow Growth
2012 23.474.000
2013 161.535.000 85.47%
2014 64.059.000 -152.17%
2015 -6.641.000 1064.6%
2016 -212.355.000 96.87%
2017 -205.227.000 -3.47%
2018 -277.441.000 26.03%
2019 -406.826.000 31.8%
2020 -239.800.000 -69.65%
2021 -147.418.000 -62.67%
2022 99.294.000 248.47%
2023 484.344.000 79.5%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Camurus AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2012 24.735.000
2013 163.064.000 84.83%
2014 69.429.000 -134.86%
2015 -5.657.000 1327.31%
2016 -207.788.000 97.28%
2017 -203.084.000 -2.32%
2018 -274.084.000 25.9%
2019 -404.364.000 32.22%
2020 -238.832.000 -69.31%
2021 -143.427.000 -66.52%
2022 101.199.000 241.73%
2023 485.696.000 79.16%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Camurus AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2012 1.261.000
2013 1.529.000 17.53%
2014 5.370.000 71.53%
2015 984.000 -445.73%
2016 4.567.000 78.45%
2017 2.143.000 -113.11%
2018 3.357.000 36.16%
2019 2.462.000 -36.35%
2020 968.000 -154.34%
2021 3.991.000 75.75%
2022 1.905.000 -109.5%
2023 1.352.000 -40.9%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Camurus AB (publ) Equity
Year Equity Growth
2012 40.210.000
2013 50.047.000 19.66%
2014 123.457.000 59.46%
2015 640.557.000 80.73%
2016 564.418.000 -13.49%
2017 385.000.000 -46.6%
2018 252.324.000 -52.58%
2019 631.634.000 60.05%
2020 847.441.000 25.47%
2021 848.908.000 0.17%
2022 994.671.000 14.65%
2023 1.488.315.000 33.17%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Camurus AB (publ) Assets
Year Assets Growth
2012 57.405.000
2013 111.656.000 48.59%
2014 207.668.000 46.23%
2015 816.349.000 74.56%
2016 639.776.000 -27.6%
2017 475.934.000 -34.43%
2018 364.724.000 -30.49%
2019 772.046.000 52.76%
2020 1.044.098.000 26.06%
2021 1.081.897.000 3.49%
2022 1.305.488.000 17.13%
2023 1.841.665.000 29.11%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Camurus AB (publ) Liabilities
Year Liabilities Growth
2012 15.434.000
2013 57.032.000 72.94%
2014 84.211.000 32.27%
2015 175.791.000 52.1%
2016 75.358.000 -133.27%
2017 90.934.000 17.13%
2018 112.400.000 19.1%
2019 140.412.000 19.95%
2020 176.270.000 20.34%
2021 232.989.000 24.34%
2022 310.817.000 25.04%
2023 353.350.000 12.04%

Camurus AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
27.96
Net Income per Share
7.98
Price to Earning Ratio
73.11x
Price To Sales Ratio
20.16x
POCF Ratio
54.03
PFCF Ratio
52.79
Price to Book Ratio
22.58
EV to Sales
19.44
EV Over EBITDA
52.79
EV to Operating CashFlow
50.33
EV to FreeCashFlow
50.91
Earnings Yield
0.01
FreeCashFlow Yield
0.02
Market Cap
32,46 Bil.
Enterprise Value
31,30 Bil.
Graham Number
68.12
Graham NetNet
18.15

Income Statement Metrics

Net Income per Share
7.98
Income Quality
1.35
ROE
0.37
Return On Assets
0.23
Return On Capital Employed
0.35
Net Income per EBT
0.79
EBT Per Ebit
1.03
Ebit per Revenue
0.31
Effective Tax Rate
0.21

Margins

Sales, General, & Administrative to Revenue
0.03
Research & Developement to Revenue
0.34
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.92
Operating Profit Margin
0.31
Pretax Profit Margin
0.32
Net Profit Margin
0.25

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
10.8
Free CashFlow per Share
10.68
Capex to Operating CashFlow
-0.01
Capex to Revenue
-0
Capex to Depreciation
-0.64
Return on Invested Capital
0.3
Return on Tangible Assets
0.25
Days Sales Outstanding
58.37
Days Payables Outstanding
231.09
Days of Inventory on Hand
322.61
Receivables Turnover
6.25
Payables Turnover
1.58
Inventory Turnover
1.13
Capex per Share
-0.12

Balance Sheet

Cash per Share
20,03
Book Value per Share
25,84
Tangible Book Value per Share
25.84
Shareholders Equity per Share
25.84
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-1.95
Current Ratio
5.05
Tangible Asset Value
1,49 Bil.
Net Current Asset Value
1,21 Bil.
Invested Capital
0
Working Capital
1,25 Bil.
Intangibles to Total Assets
0
Average Receivables
0,27 Bil.
Average Payables
0,08 Bil.
Average Inventory
105367500
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Camurus AB (publ) Dividends
Year Dividends Growth
2022 0

Camurus AB (publ) Profile

About Camurus AB (publ)

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

CEO
Mr. Fredrik Tiberg
Employee
213
Address
Ideon Science Park
Lund, 223 70

Camurus AB (publ) Executives & BODs

Camurus AB (publ) Executives & BODs
# Name Age
1 Mr. Fredrik Tiberg
President, Chief Executive Officer, CSO & Director
70
2 Ms. Maria Lundqvist
Global Head of Human Resources
70
3 Mr. Fredrik Joabsson
Chief Business Development Officer
70
4 Mr. Jon U. Garay Alonso
Chief Financial Officer
70
5 Mr. Torsten Malmstrom
Chief Technology Officer
70
6 Mr. Rein Piir B.Sc.
Vice President of Investor Relations
70
7 Mr. Markus Johnsson
Senior Vice President of R&D
70
8 Mr. Richard Jameson
Chief Commercial Officer
70
9 Mr. Alberto Pedroncelli
Chief Medical Officer
70

Camurus AB (publ) Competitors